Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes.

摘要: . Type 2 diabetes mellitus (T2DM) treatment should not increase cardiovascular (CV) risk and at best could provide benefit beyond lowering glucose. Pioglitazone has demonstrated a favorable CV profile relative to other oral antidiabetic drugs (OADs) in outcome observational studies. This randomized, double-blind, parallel-group controlled study examined circulating biomarkers of T2DM patients receiving fixed-dose combination (FDC) pioglitazone/metformin compared with the respective monotherapies. Patients stable glycosylated hemoglobin (HbA(1c) ) for 3 months taking no OADs were treated pioglitazone 15mg/metformin 850mg FDC twice daily (bid), 15mg bid, or metformin bid 24 weeks. increased high-density lipoprotein cholesterol by 14.20% 9.88%, respectively, vs an 6.09% (P<.05, FDC). Triglycerides decreased all three treatments -5.95%, -5.54% -1.78%, respectively; P=not significant). significantly small low-density large particle concentrations. Reductions high-sensitivity C-reactive protein greater groups. Increases adiponectin significant groups (P<.0001 metformin). Overall, adverse events higher FDC. Thus, resulted improved levels biomarkers, which better than equal monotherapy.